Atlas Trials

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Clinical trial NCT01566695 · COMPLETED

Trial details

NCT number
NCT01566695
Sponsor
Celgene
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Myelodysplastic Syndrome
Start date
2013-04-26
Primary completion
2019-01-25
Enrollment
216

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.